Bioscience & Pharmaceutical

WILMINGTON — Incyte has announced promising results from a third phase of a trial studying Monjuvi, including...

DOVER – A new pharmaceutical and supplement company is headed for Kent County this holiday season and...

WILMINGTON — Clinical trials at Prelude Therapeutics have made significant headway with Phase 1 results of one...

Scores of people gathered at the Hotel du Pont to celebrate Incyte as the honoree of the Pete du Pont Foundation Freedom award Tuesday night.

The new Director of University and Industry Relations, Life Sciences believes her role is to serve as a voice for the biotech industry and university.

DOVER — Wilmington University is paving the way for an improved workforce within the scientific community with...

NEWARK — A room full of women in STEM fields gathered on Thursday, Sept. 26 at Deerfield...

Niktimvo is approved for treatment of chronic graft-versus-host disease. Incyte and its partner developer forecast that it may earn $650 million in net profit.

AstraZeneca has announced it will invest millions in one of its state-of-the-art facilities that focuses on packing protein therapeutics in a growing area in its portfolio.

Hervé Hoppenot, president and CEO of Delaware’s pioneering biopharmaceutical company Incyte who has helped guide the company to new heights, has been named the 2024 Pete du Pont Freedom Award honoree.